Cenerimod
Sponsors
Viatris Innovation GmbH
Conditions
HealthyHealthy SubjectsHealthy VolunteersHepatic ImpairmentLupus Erythematosus, SystemicNephritis, LupusRenal ImpairmentSystemic Lupus Erythematosus
Phase 1
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
CompletedNCT02472795
Start: 2015-06-01End: 2017-02-28Updated: 2026-07-29
A Study to Evaluate Cenerimod in Healthy Male Subjects
CompletedNCT02914223
Start: 2016-09-01End: 2016-12-01Updated: 2025-09-22
Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
CompletedNCT04052360
Start: 2019-08-07End: 2019-11-02Updated: 2025-09-22
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod
CompletedNCT04819464
Start: 2021-08-25End: 2024-08-18Updated: 2025-09-22
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
CompletedNCT05004311
Start: 2021-09-27End: 2023-08-10Updated: 2025-09-22
Phase 3
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Active, not recruitingNCT05648500
Start: 2022-12-13End: 2027-09-30Updated: 2026-09-15
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Active, not recruitingNCT05672576
Start: 2023-06-26End: 2027-06-30Updated: 2026-09-15
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Enrolling by invitationNCT06475742
Start: 2024-07-30End: 2032-09-01Target: 680Updated: 2026-09-11
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
RecruitingNCT07201129
Start: 2026-02-09End: 2030-02-01Target: 300Updated: 2026-07-30